World Drug Sales Up 6% In Jan-Feb

11 May 1997

Retail pharmaceutical sales in the world's 10 leading markets grew 6%overall to a value of $26.36 billion in January-February 1997, compared with the first two months of 1996, say new data from IMS International.

The biggest rise was in the USA, up 10% to $10.66 billion, with Canada up 8% to $676 million. France and Spain rose 7%, to $2.62 billion and $845 million respectively, while Italy was up 6% to $1.54 billion, and the UK rose 5% to $1.19 billion. Belgium was up 4% to $328 million, while Japan rose 1% to $6.26 million and Dutch sales were flat at $313 million. Germany fell 1% to $2.58 billion.

By therapeutic category, the biggest increase was for anti-infectives, up 13% to $3.16 billion, followed by parasitologicals, rising 12% to $48 million and central nervous system treatments, up 10% to $3.59 billion. Sales of dermatologicals were flat at $988 million, and hospital solutions fell 1% to $283 million.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight